Fig 1.
Flow-chart displaying study design and treatment allocation.
Table 1.
Descriptive variables.
Fig 2.
Effect of imipramine on quantitative sensory tests.
Imipramine effect on pressure pain detection (PPDT, a) and tolerance thresholds (PPTT, b), and on electrical single pain detection threshold (ESPT, c) and electrical repeated pain threshold (ERPT, d) in all patients (n = 50), independent of genotype. GMR = geometric mean ratio.
Fig 3.
Interaction of drug effect and genotype.
Effect of imipramine (filled symbols) vs. placebo (open symbols) on electrical pain detection threshold with a single (ESPT) or repeated stimulus (ERPT), on pressure pain detection (PPDT) and tolerance thresholds (PPTT) for intermediate (squares) and extensive (circles) CYP2D6 metabolizers. The interaction between imipramine effect and CYP2D6 genotype is suggested by the diverging lines within the first 60 minutes in intermediate metabolizers (squares), whereas no such divergence is seen in extensive metabolizers (circles).
Table 2.
Quantitative sensory tests in intermediate and extensive metabolizers.
Table 3.
Occurrence of nausea, dizziness and sedation after drug intake.